secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001628280-23-018159
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q1 2023: Net loss $23.4M; cash $144.3M; zero-shot AI breakthrough; new partnerships
--------------------------------------------------------------------------------

- Revenue $1.3M (up from $0.8M YoY); net loss narrowed to $23.4M from $29.5M.
- Cash and investments $144.3M at March 31, 2023; runway into late 2025.
- Achieved first zero-shot generative AI design of de novo therapeutic antibodies; hit rate 5-30x above baselines.
- Partnered with Oxford Kennedy Institute (immune diseases) and Aster Insights (oncology) to apply AI platform.
- Guidance: at least 10 new Active Programs in 2023; gross cash use ~$90M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023018159/0001628280-23-018159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023018159/absc-20230515.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-018159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer